Bibliographic Details
| Title: |
Quantitative 68Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177Lu-PSMA-617 (VISION Trial) |
| Authors: |
Kuo, Phillip H., Morris, Michael J., Hesterman, Jacob, Kendi, A. Tuba, Rahbar, Kambiz, Wei, Xiao X., Fang, Bruno, Adra, Nabil, Garje, Rohan, Michalski, Jeff M., Chi, Kim, Bono, Johann de, Fizazi, Karim, Krause, Bernd, Sartor, Oliver, Tagawa, Scott T., Ghebremariam, Samson, Brackman, Marcia, Wong, Connie C., Catafau, Ana M., Benson, Taylor, Armstrong, Andrew J., Herrmann, Ken |
| Source: |
Radiology; August 2024, Vol. 312 Issue: 2 |
| Abstract: |
Visual 68Ga-PSMA-11 PET/CT eligibility criteria helped identify participants with metastatic castration-resistant prostate cancer who benefitted from 177Lu-PSMA-617 therapy in the VISION trial, with higher 68Ga-PSMA-11 uptake associated with improved outcomes. |
| Database: |
Supplemental Index |
